Clinical trials: Neoplasms, Connective and Soft Tissue
Plantar Fibromatosis
Long-Term Safety, Efficacy, and Durability of EN3835 in the Treatment and Retreatment of Plantar Fibromatosis
Assess the long-term safety and efficacy of EN3835 in participants who have participated in a parent placebo-controlled study of EN3835 (EN3835-222, NCT05152173) and assess the efficacy and safety of EN3835 in the treatment and…
- Trial name
- NCT05254457
- Testing
- EN3835
- Where
- 27 sites in United States
- Volunteers
- 145 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Embolization, Vascular Tumor
Evaluation of a Simple-Prep Controlled Embolic
The objective of this study is to evaluate the safety and effectiveness of the GPX® Embolic Device when used as indicated for embolization requiring distal vessel penetration in 114 subjects in up to 25 investigational sites in…
- Conditions
- Embolization, Vascular Tumor, Renal Angiomyolipoma, Renal Cell Carcinoma
- Trial name
- GPX (NCT06453642)
- Testing
- GPX® Embolic Device
- Where
- 20 sites in United States, Canada and 1 more
- Volunteers
- 114 people
- Sponsor
- Fluidx Medical Technology, Inc.
Leiomyosarcoma, Liposarcoma
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
This study will evaluate the safety and efficacy of MASCT-I combined with Doxorubicin and Ifosfamide for first-line treatment in patients with advanced soft tissue sarcoma.
- Conditions
- Leiomyosarcoma, Liposarcoma, Synovial Sarcoma, Angiosarcoma
- Trial name
- NCT06277154
- Testing
- MASCT-I, Doxorubicin, Ifosfamide
- Where
- China
- Volunteers
- 148 people
- Sponsor
- HRYZ Biotech Co.
Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
This study is conducted in two phases. The phase 1 portion of the study evaluates the safety, tolerability, pharmacokinetics (PK), recommended phase 2 dose (RP2D), and effectiveness of lurbinectedin monotherapy in pediatric…
- Conditions
- Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma, Ewing Sarcoma
- Trial name
- NCT05734066
- Testing
- Lurbinectedin
- Where
- 16 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Jazz Pharmaceuticals
Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS)
Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma
This study is open to adults with specific types of advanced soft tissue sarcoma. People with undifferentiated pleomorphic sarcoma (UPS) or myxofibrosarcoma (MFS) can join the study if they have a normal version of the TP53 gene.
- Conditions
- Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS), Myxofibrosarcoma (MFS)
- Trial name
- NCT06370871
- Testing
- Brigimadlin, Ezabenlimab, Gemcitabine
- Sponsor
- Boehringer Ingelheim
Uterine Fibroids
Safety and Efficacy of 25 and 50 mg Doses of Proellex® in Treating the Recurrence of Uterine Fibroid Symptoms
Subjects with symptomatic uterine fibroids will be enrolled and will receive daily oral study medication for 4 months. This will be followed by a 6 month off-drug interval until there is a return of significant symptomatology.
- Trial name
- NCT00874302
- Testing
- Proellex
- Where
- 20 sites in United States, Brazil
- Sponsor
- Repros Therapeutics Inc.
Leiomyosarcoma
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
The primary objective of this phase III trial is to evaluate whether the combination of lurbinectedin plus doxorubicin given as first line treatment for metastatic leiomyosarcoma (LMS) prolongs the progression-free survival (PFS)…
- Trial name
- SaLuDo (NCT06088290)
- Testing
- Lurbinectedin, Doxorubicin
- Where
- 97 sites in United States, Austria and 10 more
- Volunteers
- 469 people
- Sponsor
- PharmaMar
Colorectal Cancer, Triple Negative Breast Cancer
Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour
This clinical trial is an open-label, single-centre, dose escalation, phase I study designed to investigate the safety and tolerability of Haploidentical / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted Gamma Delta…
- Conditions
- Colorectal Cancer, Triple Negative Breast Cancer, Sarcoma, Nasopharyngeal Carcinoma
- Trial name
- NCT04107142
- Testing
- Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell
- Where
- Malaysia
- Volunteers
- 10 people
- Sponsor
- CytoMed Therapeutics Pte Ltd
Soft Tissue Sarcoma
A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma
The purpose of this study is to evaluate the safety of ifosfamide when added to the combination regimen of olaratumab and doxorubicin in participants with advanced or metastatic soft tissue sarcoma (STS).
- Trial name
- NCT03283696
- Testing
- Olaratumab, Doxorubicin, Ifosfamide
- Where
- 6 sites in United States, Germany and 1 more
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Metastatic Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma
Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma
This is a phase 2b, randomized, open-label, prospective, multicenter study comparing treatment with INNO 206 to doxorubicin in subjects with metastatic, locally advanced, or unresectable soft tissue sarcomas who have not been…
- Conditions
- Metastatic Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma
- Trial name
- NCT01514188
- Testing
- INNO-206, Doxorubicin
- Where
- 34 sites in United States, Australia and 5 more
- Volunteers
- 126 people
- Sponsor
- ImmunityBio, Inc.
Synovial Sarcoma, Myxoid Liposarcoma
Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel
The purpose of this expanded access protocol (EAP) is to provide controlled access to Afamitresgene autoleucel, suspension for intravenous infusion that does not meet the commercial release specification (NC afami-cel).
- Trial name
- NCT06617572
- Testing
- Non-conforming afamitresgene autoleucel
- Where
- 11 sites in United States
- Sponsor
- USWM CT, LLC
Gastrointestinal Stromal Tumor
Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study Termination
Continuation of drug supply in Chinese patients after CAMN107DBR01study termination.
- Trial name
- MACS2226 (NCT01613053)
- Testing
- Glivec
- Where
- 3 sites in China
- Sponsor
- Novartis Pharmaceuticals
Synovial Sarcoma
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma
This study is being conducted to test the safety and efficacy of ramucirumab in combination with other chemotherapy in the treatment of relapsed, recurrent, or refractory synovial sarcoma (SS) in children and young adults.
- Trial name
- NCT04145700
- Testing
- Ramucirumab, Gemcitabine, Docetaxel
- Where
- 56 sites in United States, Australia and 8 more
- Volunteers
- 23 people
- Sponsor
- Eli Lilly and Company
Full-thickness Skin Defects, Degloving Injuries
RECELL® System Combined With Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction
A prospective randomized within-subject controlled study to compare the clinical performance of conventional autografting with and without the RECELL system on acute non-burn full-thickness skin defects.
- Conditions
- Full-thickness Skin Defects, Degloving Injuries, Crush Injuries, Laceration of Skin
- Trial name
- NCT04091672
- Testing
- Control Intervention (Conventional Autograft), Investigational Intervention (RECELL + more widely meshed autograft)
- Where
- 18 sites in United States
- Volunteers
- 65 people
- Sponsor
- Avita Medical
Mesothelioma, Non Small Cell Lung Cancer
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the…
- Conditions
- Mesothelioma, Non Small Cell Lung Cancer, Malignant Peripheral Nerve Sheath Tumors, Solid Tumor
- Trial name
- NCT05245500
- Testing
- MRTX1719
- Where
- 25 sites in United States
- Volunteers
- 336 people
- Sponsor
- Bristol-Myers Squibb
Hepatotoxicity, Tenosynovial Giant Cell Tumor
A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment
A study to evaluate the long-term risk of hepatic failure with TURALIO™ (pexidartinib) and the mechanism of liver injury based upon optional liver biopsy information among patients who received or are receiving TURALIO™…
- Trial name
- NCT04635111
- Testing
- TURALIO™
- Where
- 6 sites in United States
- Sponsor
- Daiichi Sankyo
Leiomyoma, Uterine Fibroids
Fibroid Ablation Study - Large Fibroids
The purpose of this study is to establish the effectiveness and confirm the safety of the VizAblate System in the ablation of large (> 5 cm) symptomatic uterine fibroids.
- Conditions
- Leiomyoma, Uterine Fibroids, Menorrhagia
- Trial name
- FAST-L (NCT01539187)
- Testing
- VizAblate System
- Where
- 10 sites in Mexico, Netherlands and 1 more
- Volunteers
- 6 people
- Sponsor
- Gynesonics
Uterine Fibroids, Bleeding
Study to Evaluate the Safety and Effectiveness of MRgFUS Compared With Myomectomy for the Treatment of Uterine Fibroids
The objective of this trial is to evaluate the safety and efficacy of ExAblate for the treatment of uterine fibroids. Women, seeking treatment for symptomatic uterine leiomyomata will be eligible for the study.Women who agree to…
- Conditions
- Uterine Fibroids, Bleeding, Pelvic Pain
- Trial name
- NCT01328067
- Testing
- Exablate 2100, Myomectomy
- Where
- United Kingdom
- Sponsor
- InSightec
Cancer
Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned
The purpose of this study is to determine the recommended dose of I-131-CLR1404, a radiolabeled therapy compound, for treating subjects with cancer that does not respond to treatment or has returned.
- Trial name
- NCT01495663
- Testing
- I-131-CLR1404
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Cellectar Biosciences, Inc.
Uterine Fibroids
MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids
This is a prospective, nonrandomized, multi-center study to evaluate the safety and effectiveness of ExAblate in the treatment of uterine fibroids.
- Trial name
- NCT00166270
- Testing
- ExAblate 2000
- Where
- 6 sites in United States
- Volunteers
- 70 people
- Sponsor
- InSightec